Email Us
View Reports

Global Human Microbiome-based Drugs and Diagnostics Market Analysis with Forecasts to 2022 | Growth Opportunities

  • ID : 615988536  |  
  • Published : May-2017  |  
  • Region : Global  |  
  • Pages : 124   |  
  • Publisher : BCC Research

Report Scope:

The scope of the study includes the major microbiome-based drugs and diagnostics that are likely to be commercialized within the next eight years. Each product within each market is analyzed to determine its market status, market potential during the time period of 2018 to 2024. Microbiome intellectual property, investments and collaborations are discussed.

Influencing factors, industry structure, challenges facing the industry and patent status are discussed. BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. We profile 25+ companies participating in this rapidly developing and evolving sector.

Report Includes:

- An overview of the global markets for human microbiome-based drugs and diagnostics.

- Analyses of global market trends, with estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2024.

- Coverage of areas and applications where these technologies are applicable, such as cancer, diabetes, allergic disorders, irritable bowel disorders, celiac disease, and other G.I. disorders.

- An in-depth look at macro-level trends affecting this sector.

- Market intelligence on the technologies and platforms currently being deployed to develop these drugs and diagnostics.

- Specific emphasis on the products in development for various diseases, including the specific forecasts for these products by disease and geography.

- A look at the current level of investments in the sector, intellectual property development, and future of this sector.

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives

Reasons for Doing This Study

Intended Audience

Scope of Report

Information Sources

Methodology

Geographic Breakdown

Analyst's Credentials

Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Microbiome Overview

Scientific Background

Human Microbiome in Health and Disease

Advances in Microbiome Research

Focus Areas for Microbiome-Based Drugs and Diagnostics

Microbiome-Based Drugs: Product Development Strategies

Current Challenges in Microbiome Drug Development

Human Microbiome Project

MetaHIT Consortium

Public Sector Initiatives in Microbiome Research

Key Goals of the Human Microbiome Project

Key Achievements of the Human Microbiome Project

Key Goals of MetaHIT Initiative

Chapter 4 Human Microbiome-Based Drugs Market

Cancer

Obesity

Type 2 Diabetes

Ulcerative Colitis and Crohn's Disease

Clostridium Difficle Infection

Lactose Intolerance

Dental caries

Recurrent Bacterial Vaginosis and Urinary Tract Infection

Skin Diseases

Hyperoxaluria

Urea Cycle Disorder

Celiac Disease

Phenylketonuria

Non-alcoholic Steatohepatitis (NASH)

Background

Microbiome and Cancer

Microbiome-based Drugs for Cancer: Review of Drugs in Development

Market for Microbiome-based Drugs for Cancer

Background

Microbiome and Obesity

Microbiome-based Drugs for Obesity: Review of Drugs in Development

Market for Microbiome-based Drugs for Obesity

Background

Microbiome and Type 2 Diabetes

Microbiome-based Drugs in Type 2 Diabetes: Review of Drugs in Development

Market for Microbiome-based Drugs for Type 2 Diabetes

Background

Microbiome and Ulcerative Colitis/Crohn's Disease

Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease: Review of Drugs in Development

Market for Microbiome-Based Products for Ulcerative Colitis and Crohn's Disease

Background

Microbiome and Clostridium Difficle Infection

Microbiome-based Drugs for Clostridium Difficle Infection: Review of Drugs in Development

Market for Microbiome-based Drugs for Clostridium Difficle Infection

Background

Microbiome and Lactose Intolerance

Microbiome-based Drugs for Lactose Intolerance: Review of Drugs in Development

Market for Microbiome-based Product for Lactose Intolerance

Background

Microbiome and Dental Caries

Microbiome-based Drugs for Dental Caries Review of Drugs in Development

Market for Microbiome-based Products for Dental Caries

Background

Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection

Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection: Drugs in Development

Market for Microbiome-based Products for Recurrent Bacterial Vaginosis and UTI

Background

Microbiome and Skin Diseases

Microbiome-based Drugs for Skin Diseases: Review of Drugs in Development

Market for Microbiome-based Drugs for Skin Diseases

Background

Microbiome and Hyperoxaluria

Microbiome-based Drugs for Hyperoxaluria: Review of Drugs in Development

Market for Microbiome-based Products for Hyperoxaluria

Background

Microbiome and Urea Cycle Disorder

Microbiome-based Drugs for Urea Cycle Disorder: Review of Drugs in Development

Market for Microbiome-Based Drugs for Urea Cycle Disorder

Background

Microbiome and Celiac Disease

Microbiome-Based Drugs for Celiac Disease: Review of Drugs in Development

Market for Microbiome-based Products for Celiac Disease

Background

Microbiome and Phenylketonuria

Microbiome-based Drugs for Phenylketonuria: Review of Drugs in Development

Market for Microbiome-based Products for Phenylketonuria

Background

Microbiome and Non-alcoholic Steatohepatitis

Microbiome-based Drugs for Non-alcoholic Steatohepatitis: Review of Drugs in Development

Market for Microbiome-based Products for Non-alcoholic Steatohepatitis

Microbiome-based Products for Hepatic Encephalopathy

Microbiome and Hepatic Encephalopathy

Microbiome-based Drugs for Hepatic Encephalopathy: Review of Drugs in Development

Market for Microbiome-based Drugs for Hepatic Encephalopathy

Drug Development Strategies

Microbiome-Based Drugs as Immune System Activators

Microbiome-Based Drugs as an Add-on to Immuno-Oncology Drugs

Microbiome-Based Drugs as Probiotic Mixtures

Microbiome-Based Drugs as Chemotherapy Adjuncts

Microbiome-Based Drugs in Development for Cancer

Micabodies (AvidBiotics)

Oncobiotics (Evelo Biosciences)

SER-155 (Seres Therapeutics)

Symberix Compound (Symberix)

MRX581 (4D Pharma)

AG-013 (Intrexon)

Microbial Mechanism of Disease in Obesity

Microbiota Associated with Obesity

Drug Development Strategies

Drugs in Development for Obesity

NM-504 (Microbiome Therapeutics)

NM-313 (Microbiome Therapeutics)

Fecal Microbiota Transplant (Seres Therapeutics)

Drug Development Strategies

Drugs in Development

NM-504 (Microbiome Therapeutics)

Bovin Colostrum (Immuron)

CP-001 (Caelus Health)

Seres Diabetes Program (Seres Therapeutics)

Microbiota Associated with Ulcerative Colitis and Crohn's Disease

Drugs in Development

EB-80818 (Enterome Biosciences)

EB-110 (Enterome Biosciences)

EB-120 (Enterome Biosciences)

SER-287 (Seres Therapeutics)

SGM-019 (Second Genome)

VT-301 (ViThera Pharmaceuticals)

RBX-8225 (Rebiotix)

AG-014 (Intrexon)

Market for Microbiome-based Drugs for Ulcerative Colitis

Market for Microbiome-Based Drugs for Crohn's Disease

Drug Development Strategies

Drugs in Development

VE-202 (Vedanta Biosciences)

SYN-004 (Synthetic Biologics)

SER-262/SER-109 (Seres Therapeutics)

Avidocin Proteins (AvidBiotics)

DAV-132 (DA Volterra)

CBM-588 (Osel Inc.)

RBX-2660 (Rebiotix)

Drug Development Strategies

Drugs in Development

RP-G28 (Ritter Pharmaceuticals)

Drug Development Strategies

Drugs in Development

C16-G2 (C3 Jian Inc.)

Drug Development Strategies

Drugs in Development

Acne

Rosacea

Atopic Dermatitis

Acne

Atopic Dermatitis

Rosacea

Drug Development Strategies

Drugs in Development

B-244 (AOBiome)

Drug Development Strategies

Drugs in Development

Drug Development Strategies

Drugs in Development

Drug Development Strategies

Drugs in Development

Drug Development Strategies

Drugs in Development

Drug Development Strategies

Drugs in Development

Background

Drug Development Strategies

Drugs in Development

Chapter 5 Human Microbiome-based Diagnostics Market

Microbiome Diagnostics: Overview

Microbiome Diagnostics: Technologies

Microbiome Diagnostics: Applications

Microbiome Diagnostics: Industry Collaborations

Market for Microbiome Diagnostics

Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease

Microbiome-based Diagnostics for Cancer

Microbiome Diagnostics for Women's Health

Microbiome Diagnostics for Dental caries

Overview

Companion Diagnostics in Development

IBD-210

IBD-110

Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease

Overview

Companion Diagnostics in Development

Oricol

Market for Microbiome-based Diagnostics for Cancer

Overview

Market for Microbiome Diagnostics for Women's Health

Overview

Microbiome-based Diagnostics in Development

Market for Microbiome-based Diagnostic for Dental Caries

Chapter 6 Microbiome Intellectual Property, Investments and Collaborations

Intellectual Property

Investments and Collaborations

Overview

Microbiome Patent Segments

Patents by Disease Area

Investments: Overview

Public Sector Investments

Private Sector Investments

Collaborations: overview

Microbiome Public Databases Overview

Clostridium Difficle Infection

Irritable Bowel Disorders

Diabetes and Obesity

Cancer

Lactose Intolerance

Hyperoxaluria

Recurrent Bacterial Vaginosis and Urinary tract infection

Dental Caries

Urea Cycle Disorders

Human Microbiome Initiative

MetaHIT Initiative

Venture Capital Investments

Initial Public Offerings

Industry Collaborations

Vedanta Biosciences/Johnson & Johnson

Seres Therapeutics/Nestle Health Science

Enterome Biosciences/Bristol-Meyers Squibb Co. (BMS)

Enterome Biosciences/Abbvie

Enterome Biosciences/Takeda

Synlogic Inc./AbbVie

Second Genome/Johnson & Johnson

Second Genome/Pfizer

Industry/Academic Collaborations

Enterome Biosciences/Mayo Clinic

Janssen Microbiome Institute/DayTwo Ltd. and Weizmann Institute

Vedanta Biosciences/NYU Langone Medical Center

Seres Therapeutics/Massachusetts General Hospital (MGH)

Seres Therapeutics/Mayo Clinic

Seres Therapeutics/University of Pennsylvania

Second Genome/The American Gut Project

Second Genome/King's College, London

Whole Biome/Mayo Clinic

American Gut Project Database

Integrative Human Microbiome Project Database

Human Oral Microbiome Database

Chapter 7 Company Profiles

4D PHARMA

AVIDBIOTICS INC.

AOBIOME LLC

AXIAL BIOTHERAPEUTICS

C3 JIAN INC.

CAELUS HEALTH

DA VOLTERRA

ELIGO BIOSCIENCES

ENTEROME BIOSCIENCES

EVELO BIOSCIENCES

EVOLVE BIOSYSTEMS

METABIOMICS

MICROBIOME THERAPEUTICS

ORIGIN SCIENCES LTD.

OSEL INC.

OXTHERA

RITTER PHARMACEUTICALS

REBIOTIX INC.

SECOND GENOME

SERES THERAPEUTICS

SYMBERIX

SYNLOGIC BIOTICS

SYNTHETIC BIOLOGICS

UBIOME INC.

VEDANTA BIOSCIENCES

VITHERA PHARMACEUTICALS

4D Pharma Pipeline

AvidBiotics Pipeline

Aobiome pipeline

C3 jian pipeline

Caelus Health Pipeline

Da Volterra Pipeline

Enterome Pipeline

Microbiome Therapeutics Pipeline

Osel Pipeline

Oxthera Pipeline

Ritter Pharmaceuticals Pipeline

Rebiotix Pipeline

Second Genome Pipeline

Seres Therapeutics Pipeline

Symberix Pipeline

Synlogic Pipeline

Synthetic Biologics Pipeline

Vedanta Biosciences Pipeline

ViThera Pharmaceuticals Pipeline

List of Tables

Summary

Table 1 : Summary Table: Global Market for Human Microbiome Based Drugs by Disease Indication, through 2024

Table 2 : Focus Disease Areas for Microbiome Research

Table 3 : Microbiome Drug Development Approaches

Table 4 : U.S. Prevalence of Cancer, through 2024

Table 5 : Microbiota Associated with Cancers

Table 6 : Microbiome-based Drugs in Development for Cancer

Table 7 : U.S. Market Shares of Microbiome-based Drugs for Cancer, by Company, 2018-2024

Table 8 : U.S. Patient Volumes for Microbiome-based Drugs for Cancer, by Company, through 2024

Table 9 : U.S. Market for Microbiome-based Drugs for Cancer, by Company, through 2024

Table 10 : Rest of the World Market for Microbiome-based Drugs for Cancer, by Country/Region, through 2024

Table 11 : U.S. Prevalence of Obesity, through 2024

Table 12 : Microbiota Associated with Obesity

Table 13 : Microbiome-based Drugs in Development for Obesity

Table 14 : U.S. Market Shares of Microbiome-based Drugs for Obesity, by Company, 2018-2024

Table 15 : U.S. Patient Volumes for Microbiome-based Drugs for Obesity, by Company, through2024

Table 16 : U.S. Market for Microbiome-based Drugs for Obesity, by Company, through 2024

Table 17 : U.S. Prevalence of Type 2 Diabetes, through 2024

Table 18 : Microbiota Associated with Type 2 Diabetes

Table 19 : Microbiome-based Drugs in Development for Type 2 Diabetes

Table 20 : U.S. Market Shares of Microbiome-based Drugs for Type 2 Diabetes, by Company, 2018-2024

Table 21 : U.S. Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024

Table 22 : U.S. Market for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024

Table 23 : Rest of the World Market for Microbiome-based Drugs for type 2 Diabetes, by Country/Region, through 2024

Table 24 : U.S. Prevalence of Ulcerative Colitis and Crohn's Disease, through 2024

Table 25 : Microbiome-based Drugs in Development for Ulcerative Colitis and Crohn’s Disease

Table 26 : U.S. Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024

Table 27 : Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn’s Disease, through 2024

Table 28 : U.S. Market Shares of Microbiome-based Drugs for Ulcerative Colitis, by Company, 2018-2024

Table 29 : U.S. Patient Volumes for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024

Table 30 : U.S. Market for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024

Table 31 : Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis, by Country/Region, through 2024

Table 32 : U.S. Market Shares of Microbiome-based Drugs for Crohn's Disease, by Company, 2018-2024

Table 33 : U.S. Patient Volumes for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024

Table 34 : U.S. Market for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024

Table 35 : Rest of the World Market for Microbiome-based Drugs for Crohn's Disease, by Country/Region, through 2024

Table 36 : U.S. Prevalence of Clostridium Difficle Infection, through 2024

Table 37 : Microbiome-based Drugs in Development for Clostridium Difficle Infection

Table 38 : U.S. Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by Company, 2018-2024

Table 39 : U.S. Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024

Table 40 : U.S. Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024

Table 41 : Rest of the World Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Country/Region, through 2024

Table 42 : U.S. Prevalence of Lactose Intolerance, through 2024

Table 43 : Microbiome-based Drugs in Development for Clostridium Difficle Infection

Table 44 : U.S. Market Shares of Microbiome-based Drugs for Lactose Intolerance, by Company, 2018-2024

Table 45 : U.S. Patient Volumes for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024

Table 46 : U.S. Market for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024

Table 47 : Rest of the World Market for Microbiome-based Drugs for Lactose Intolerance, by Country/Region, through 2024

Table 48 : U.S. Prevalence of Dental Caries, through 2024

Table 49 : Microbiome-based Drugs in Development for Clostridium Difficle Infection

Table 50 : U.S. Market Shares of Microbiome-based Drugs for Dental Caries, by Company, 2018-2024

Table 51 : U.S. Patient Volumes for Microbiome-based Drugs for Dental Caries, by Company, through 2024

Table 52 : U.S. Market for Microbiome-based Drugs for Dental Caries, by Company, through 2024

Table 53 : Rest of the World Market for Microbiome-based Drugs for Dental Caries, by Country/Region, through 2024

Table 54 : U.S. Prevalence of Recurrent Bacterial Vaginosis and Urinary Tract Infection, through 2024

Table 55 : Microbiome-based Drugs in Development for Recurrent Bacterial Vaginosis and Urinary Tract Infection

Table 56 : U.S. Market Shares of Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, 2018-2024

Table 57 : U.S. Patient Volumes for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024

Table 58 : U.S. Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024

Table 59 : Rest of the World Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Country/Region, through 2024

Table 60 : U.S. Prevalence of Skin Diseases, through 2024

Table 61 : Microbiome-based Drugs in Development for Skin Diseases

Table 62 : U.S. Market Shares of Microbiome-based Drugs for Skin Diseases, by Company, 2018-2024

Table 63 : U.S. Patient Volumes for Microbiome-Based Drugs for Skin Diseases, by Company, through 2024

Table 64 : U.S. Market for Microbiome-based Drugs for Skin Diseases, by Company, through 2024

Table 65 : Rest of the World Market for Microbiome-based Drugs for Skin Diseases, by Country/Region, through 2024

Table 66 : U.S. Prevalence of Hyperoxaluria, through 2024

Table 67 : Microbiome-based Drugs in Development for Skin Diseases

Table 68 : U.S. Market Shares of Microbiome-based Drugs for Hyperoxaluria, by Company, 2018-2024

Table 69 : U.S. Patient Volumes for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024

Table 70 : U.S. Market for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024

Table 71 : Rest of the World Market for Microbiome-based Drugs for Hyperoxaluria, by Country/Region, through 2024

Table 72 : U.S. Prevalence of Urea Cycle Disorder, through 2024

Table 73 : Microbiome-based Drugs in Development for Urea Cycle Disorder

Table 74 : U.S. Market Shares of Microbiome-based Drugs for Urea Cycle Disorder,by Company, 2018-2024

Table 75 : U.S. Patient Volumes for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024

Table 76 : U.S. Market for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024

Table 77 : U.S. Prevalence of Celiac Disease, through 2024

Table 78 : Microbiota Associated with Celiac Disease

Table 79 : Microbiome-based Drugs in Development for Celiac Disease

Table 80 : U.S. Market Shares of Microbiome-based Drugs for Celiac Disease, by Company, 2018-2024

Table 81 : U.S. Patient Volumes for Microbiome-based Drugs for Celiac Disease, by Company, through 2024

Table 82 : U.S. Market for Microbiome-based Drugs for Celiac Diseases, by Company, through 2024

Table 83 : U.S. Prevalence of Phenylketonuria, through 2024

Table 84 : U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024

Table 85 : U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024

Table 86 : U.S. Patient Volumes for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024

Table 87 : U.S. Market for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024

Table 88 : Rest of the World Market for Microbiome-based Drugs for Celiac Diseases, by Country/Region, through 2024

Table 89 : U.S. Prevalence of Non-alcoholic Steatohepatitis, through 2024

Table 90 : Microbiome-based Drugs in Development for Non-alcoholic Steatohepatitis

Table 91 : U.S. Market Shares of Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, 2018-2024

Table 92 : U.S. Patient Volumes for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024

Table 93 : U.S. Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024

Table 94 : Rest of the World Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Country/Region, through 2024

Table 95 : U.S. Prevalence of Hepatic Encephalopathy, through 2024

Table 96 : Microbiome-based Drugs in Development for Hepatic Encephalopathy

Table 97 : U.S. Market Shares of Microbiome-based Drugs for Hepatic Encephalopathy, by Company, 2018-2024

Table 98 : U.S. Patient Volumes for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024

Table 99 : U.S. Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024

Table 100 : Rest of the World Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Country/Region, through 2024

Table 101 : Comparison of Microbiome Sequencing Technologies

Table 102 : U.S. Market for Microbiome-based Diagnostics, by Disease Segment, through 2024

Table 103 : Rest of the World Market for Microbiome-based Diagnostics, by Country/Region, through 2024

Table 104 : U.S. Market Shares of Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, 2018-2024

Table 105 : U.S. Assay Volumes for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024

Table 106 : U.S. Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024

Table 107 : U.S. Prevalence of Microbiome-based Diagnostics for Colorectal Cancer, through 2024

Table 108 : U.S. Market Shares of Microbiome-based Diagnostics for Colorectal Cancer, by Company, 2018-2024

Table 109 : U.S. Assay Volumes for Microbiome-based Diagnostics for Colorectal Cancer, through 2024

Table 110 : U.S. Market for Microbiome-based Diagnostics for Colorectal Cancer, through 2024

Table 111 : U.S. Prevalence of Microbiome-based Diagnostics for Women's Health, through 2024

Table 112 : U.S. Market Shares of Microbiome-based Diagnostics for Women’s Health, by Company, 2018-2024

Table 113 : U.S. Assay Volumes for Microbiome-based Diagnostics for Women’s Health, through 2024

Table 114 : U.S. Market for Microbiome-based Diagnostics for Women's Health, through 2024

Table 115 : U.S. Market Shares of Microbiome-based Diagnostics for Dental Caries, by Company, 2018-2024

Table 116 : U.S. Assay Volumes for Microbiome-based Diagnostics for Dental Caries, through 2024

Table 117 : U.S. Market for Microbiome-based Diagnostics for Dental Caries, by Company through 2024

Table 118 : U.S. Patents and Patent Applications on Microbiome-based Drugs for C. Difficle Infection

Table 119 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Irritable Bowel Syndrome

Table 120 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Diabetes and Obesity

Table 121 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Cancer

Table 122 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Lactose Intolerance

Table 123 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Hyperxaluria

Table 124 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urniary Tract Infection

Table 125 : U.S. Patents and Patent Applications on Microbiome-Based Drugs for Dental Caries

Table 126 : U.S. Patents and Patent Applications on Microbiome-based Drugs for Urea Cycle Disorders

Table 127 : Venture Capital Investments in Microbiome Start-Ups

Table 128 : Initial Public Offerings by Microbiome-Based Companies

Table 129 : Industry collaborations in Microbiome-based Companies

Table 130 : 4D Pharma Pipeline

Table 131 : Avidbiotics Pipeline

Table 132 : AObiome Pipeline

Table 133 : C3 Jian Pipeline

Table 134 : Caelus Pipeline

Table 135 : Da Volterra Pipeline

Table 136 : Enterome Pipeline

Table 137 : Microbiome Therapeutics Pipeline

Table 138 : Osel Pipeline

Table 139 : Oxthera Pipeline

Table 140 : Oxthera Pipeline

Table 141 : Rebiotix Pipeline

Table 142 : Second Genome Pipeline

Table 143 : Seres Therapeutics Pipeline

Table 144 : Synlogic Pipeline

Table 145 : Synthetic Biologics Pipeline

Table 146 : Vedanta Biosciences Pipeline

Table 147 : ViThera Pharmaceuticals Pipeline

List of Figures

Figure 1 : Summary Figure A: Global Market for Human Microbiome Based Drugs and Diagnostics, 2018-2024

Figure 2 : Summary Figure B: Global Market for Human Microbiome Based Drugs by Region, 2018-2024

Figure 3 : Summary Figure C: Global Market for Human Microbiome Based Diagnostics by Region, 2018-2024

Figure 4 : Human Microbiome Based Drugs, Pipeline Projects, 2016

Figure 5 : Microbes Involved in Healthy Facial Skin

Figure 6 : Number of Patents Granted for Worldwide Microbiome-based Drugs, 2002-2016

Purchase this Market Research Report

  • SINGLE USER LICENSE
    Single user license allows one specific user to access the product.
  • TEAM LICENSE
    Team License allows multiple users to access the product.
  • CORPORATE LICENSE
    Corporate License allows users across the whole organization to access the product.

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?